Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
Merck (MRK) and Daiichi Sankyo withdrew their FDA filing for ifinatamab deruxtecan, a lung cancer therapy, due to insufficient data. They continue evaluating it in late-stage studies. MRK's shares are up 41% year-to-date. This is the second withdrawal under their 2023 partnership.
How this was made
The 30-second read
Why it matters
The withdrawal removes a near‑term catalyst, likely pressuring both stocks while opening space for competitors.
Market read
Regulatory withdrawal is a primary corporate event with immediate trading impact on MRK and DAI, and secondary implications for the oncology ADC market.
What to watch
The companies still have late‑stage studies; a positive readout could restore upside quickly.
Background
Merck and Daiichi Sankyo had been pursuing accelerated approval for an ADC targeting extensive‑stage small‑cell lung cancer.
Ticker impact
Merck withdrew its FDA accelerated‑approval filing for the ADC ifinatamab deruxtecan in extensive‑stage small‑cell lung cancer.
likely downward pressure as investors reassess the ADC pipeline
Regulatory setbacks for a high‑profile oncology asset typically lead to short‑term sell‑offs.
Market effects
May weigh on the broader oncology ADC sector and could benefit rivals GSK and Roche.
US biotech sentiment could soften; Japanese pharma (Daiichi) faces similar pressure.
Regulatory setbacks highlight FDA scrutiny, influencing global pipeline expectations.
Counterpoint
If the phase III data later proves compelling, the withdrawal could be seen as a strategic delay, offering a buying opportunity.
Key entities
- companyMerck
US pharmaceutical giant, ticker MRK.
- companyDaiichi Sankyo
Japanese pharma partner, ticker DAI.
- companyGSK
Potential beneficiary with positive ADC trial results.
- companyRoche
Potential beneficiary with positive ADC trial results.
